presentation on hemophilia slideshare

• My presentations

Auth with social network:

Download presentation

We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!

Presentation is loading. Please wait.

Hemophilia 2009.

Published by Patrick Powell Modified over 6 years ago

Similar presentations

Presentation on theme: "Hemophilia 2009."— Presentation transcript:

The Basics of Hemophilia

Hemophilia Improving quality of life …until a cure…through L ower mortality I mproved outcomes F ewer hospitalizations E ducated independent patients.

1 Maggie Constantine, MD, FRCPC Resident, Transfusion Medicine UBC TMR Journal Club – November 7, 2007.

Hemophilia B. World Federation of Hemophilia Global Survey 2008 Demographics Number of countries in this survey: 108 Percentage of world population covered.

WFH Bangkok 2004 Factor VIII - Von Willebrand Factor Inhibitors and Immune Tolerance The Key Issue in Haemophilia A.

© 2014 Direct One Communications, Inc. All rights reserved. 1 Meeting the Challenges of Managing Hemophilia: Prophylactic vs Episodic Therapy Duc Q. Tran,

BLEEDING DISORDERS AN OVERVIEW WITH EMPHASIS ON EMERGENCIES.

-HA -HB -Factor XI deficiency -Factor II deficiency -Factor V deficiency -Factor XIII deficiency -Factor VII deficiency Dental problems in Hemophilia.

This presentation is customizable for you or your child

© 2014 Direct One Communications, Inc. All rights reserved. 1 Recent Advances in Preventing Bleeding, Reducing Inhibitors, and Managing Acute Bleeding.

Initiation substances activate s by proteolysis a cascade of circulating precursor proteins which leads to the generation of thrombin which in turn converts.

The Basics of Hemophilia Nursing Working Group National Hemophilia Foundation.

© 2014 Direct One Communications, Inc. All rights reserved. 1 Hemophilia A and B: Disease Differences and the Use of Prophylactic Therapy Anna Chalmers,

Coagulation Disorders

MLAB 1227: Coagulation Keri Brophy-Martinez

Hemophilia What is Hemophilia? Hemophilia is an inherited bleeding disorder in which there is a deficiency or lack of factor VIII or factor IX clotting.

Approach to the Bleeding Patient

By: Bekim Ameti. Information On Hemophilia Hemophilia is the oldest known heredity bleeding disorder. Hemophilia has been known for thousands of years.

An Introduction to Haemophilia and related bleeding disorders M QARI, MD, FRCPA.

MISHA MAZHAR 2k10-NUST-BS-V&I-54.  Mutations in F8 or F9 genes.  Leads to lack of proteins made by these genes.  F8 responsible for making the blood.

About project

© 2024 SlidePlayer.com Inc. All rights reserved.

• Preferences

Haemophilia - PowerPoint PPT Presentation

Haemophilia

Haemophilia is an inherited state in which bleeding is caused for a long time after having an injury or surgery and painful swelling of the joints can be there after injury or even without injury. – powerpoint ppt presentation.

• Haemophilia is an inherited condition in which bleeding is caused for a long time after having an injury or surgery and painful swelling of the joints can be there either after injury or even without injury.
• Haemophilia is caused basically due to a deficiency of clotting factor and this result in increased bleeding. There are two types of Haemophilia A (clotting factor VIII deficiency), which is more common and occurs in about 1 in 5,000 births. Haemophilia B (factor IX deficiency) is less common and occurs in around 1 in about 20,000 births.
• The disease of Haemophilia is X linked and inherited from the mother, though the disease is present in males. A family history of maternal uncles or other male affected relatives on the mothers side are often present. Though many cases are due to a new acquired mutation in the genes, and in these families, no family history is present.In the X-linked variety of haemophilia, the inheritance is due to a defective gene on the X chromosome. All humans have X chromosomes, in females there are two X chromosomes, while males have one X and one Y chromosome.Only the X chromosome carries the genes related to haemophilia. A male who inherits haemophilia gene on his X chromosome will suffer from haemophilia. If a female has the defective gene on one of her X chromosomes, she is a "haemophilia carrier.The carrier does not suffer from haemophilia, but they can pass on the disease to their sons. Their daughters do not have the disease, but they may also be carriers. As mentioned earlier, this can also occur as a new mutation in families without a history of haemophilia.
• There are two main types of Haemophilia A and Haemophilia B.Haemophilia A patients has low levels of factor VIII (8), and Haemophilia B patients have low levels of factor IX (9). This is very important because patients can be treated with either factor VIII or IX injections. So it is important to know which factor is low, so that the right injection is given.
• What happens in haemophilia?Patients suffering from haemophilia bleed for a longer time than others after having any injury, injections, operations or tooth extractions. They can bleed inside (internally), and in the joints - knees, ankles, and elbows. This bleeding can damage the joints and internal bleeding (head, abdomen) may be life threatening.Haemophilia patients bleed for a very long time after injury, and often have delayed bleeding e.g. after a few days after tooth extraction or trauma. Patients with severe haemophilia they can bleed even without injury-spontaneously, this usually occurs in severe haemophilia patients.
• www.lazoi.com
• Like us on Facebook
• https//www.facebook.com/LazoiTheLife
• Follow us on Twitter
• https//www.twitter.com/lazoithelife
• Follow us on Pinterest
• https//www.in.pinterest.com/lazoithelife

PowerShow.com is a leading presentation sharing website. It has millions of presentations already uploaded and available with 1,000s more being uploaded by its users every day. Whatever your area of interest, here you’ll be able to find and view presentations you’ll love and possibly download. And, best of all, it is completely free and easy to use.

You might even have a presentation you’d like to share with others. If so, just upload it to PowerShow.com. We’ll convert it to an HTML5 slideshow that includes all the media types you’ve already added: audio, video, music, pictures, animations and transition effects. Then you can share it with your target audience as well as PowerShow.com’s millions of monthly visitors. And, again, it’s all free.

About the Developers

PowerShow.com is brought to you by  CrystalGraphics , the award-winning developer and market-leading publisher of rich-media enhancement products for presentations. Our product offerings include millions of PowerPoint templates, diagrams, animated 3D characters and more.

An official website of the United States government

The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

• Publications
• Account settings
• Browse Titles

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-.

StatPearls [Internet].

Parth Mehta ; Anil Kumar Reddy Reddivari .

Affiliations

Last Update: June 5, 2023 .

• Continuing Education Activity

Hemophilia A and B are the most common severe hereditary hemorrhagic disorders. Hemophilia A and B result from factor VIII and factor IX protein deficiency. Patients present with prolonged bleeding with or without trauma, depending on the factor activity. The principal aim of care should be to avoid and treat bleeding. The patient should receive treatment in a comprehensive treatment center where interprofessional services are offered at all times to the patients and their families. This activity reviews the epidemiology, natural history, evaluation, and management of hemophilia and also highlights the role of the interprofessional team in evaluating, managing, and improving care for patients with this condition.

• Identify the etiology of hemophilia.
• Review the evaluation of hemophilia.
• Outline the treatment and management options available for hemophilia.
• Describe interprofessional team strategies for improving care coordination and communication to advance hemophilia and improve outcomes.
• Introduction

Hemophilia, which means love (philia) of blood (hemo), is the most common severe hereditary hemorrhagic disorder. Both hemophilia A and B result from factor VIII and factor IX protein deficiency or dysfunction, respectively, and is characterized by prolonged and excessive bleeding after minor trauma or sometimes even spontaneously. There is hemophilia C as well, which occurs due to deficiency of clotting factor XI but is rare. Sometimes acquired hemophilia can present related to age or childbirth and usually resolves with appropriate treatment. Hemophilia has often been called “the disease of the kings,” as is often described in the descent of Queen Victoria of England. The earliest description in ancient history dates from the second century AD in the Babylonian Talmud about a woman who had lost her first two sons from circumcision. The earliest description in modern history was documented by the American physician Dr. John Conrad Otto. Dr. Conrad described an inheritable bleeding disorder in several families where only males born from unaffected mothers were affected. He then called them the “bleeders.” Hemophilia, as a word, was first documented by Johann Lukas Schönlein in his dissertation at the University of Zurich, Switzerland. Dr. Nasse was the first to publish the genetic description of hemophilia in Nasse’s Law: which states that hemophilia is transmitted entirely by unaffected females to their sons. [1] [2] [3] [4] [5]

Hemophilia is usually an inherited condition and is caused by the deficiency of clotting factors in the blood. It is almost always due to a defect or mutation in the gene for the clotting factor. Research has identified over 1000 mutations in the genes encoding factor VIII and IX, and around 30% are due to spontaneous mutation. The encoding genes for factors VIII and factor IX are present in the long arm of chromosome X. Both hemophilia A and B are inherited via an X-linked recessive pattern where 100% of females born from affected fathers will be carriers, and none of the males born will be affected. Female carrier mothers have a 50% chance of having affected males and a 50% chance of having carrier females. Females could also be affected if there is a complete inactivation of chromosome X through lionization, partial or complete absence of chromosome X such as in Turner Syndrome or if both parents carry the abnormal gene. [6] [7]

• Epidemiology

Hemophilia is equally distributed among all ethnic groups worldwide. The estimated frequency of hemophilia is around 1 in 10000 live births, and the number of people worldwide living with hemophilia is about 400000. [1] [8] [9]  Hemophilia A is more prevalent (80% to 85% of the total hemophilia population) than hemophilia B. It presents in 1 in 5000 live male births, whereas hemophilia B presents in 1 in 30000 live male births. Due to its X-linked inheritance pattern, geographical areas with a higher frequency of consanguineous marriages like Egypt have a higher prevalence of the disease. Hemophilia C generally occurs in 1 of every 100000 people. However, Ashkenazi Jews have a higher incidence of factor XI deficiency, which is around 8%. [10]  With new advances in early diagnoses and treatment therapies, affected individuals should expect a normal life expectancy. [6] [11]

• Pathophysiology

The process of blood clot formation involves the activation of two pathways - the extrinsic or tissue factor (TF) pathway and the intrinsic or the contact pathway. Both pathways consist of a series of cascade enzyme activation events that lead to the formation and stabilization of a blood clot by crosslinking of fibrin monomers and activation of platelets. The extrinsic pathway gets triggered by disruption of the endothelium and exposure of tissue factor (TF) in the subendothelium. Tissue factor then binds activated factor VIIa forming a complex, which activates factors IX and X into IXa and Xa, respectively. The intrinsic pathway becomes activated when factor XII, prekallikrein, and high-molecular-weight kininogen in the blood become exposed to an artificial surface. Factor XII undergoes a conformational change resulting in the small generation of factor XIIa, which activates PK to kallikrein with reciprocal activation of factor XII to XIIa. The resulting generation of factor XIIa activates factor XI to factor XIa, which converts factor IX to factor IXa. Both pathways converge at the production of factor Xa. Factor Xa converts prothrombin (factor II) into thrombin (factor IIa).

Thrombin, in turn, helps release factor VIII from the von Willebrand factor and activates into factor VIIa, activates platelets by exposing phospholipids that bind IXa, and also activates factor XIII into factor XIIIa, which helps to stabilize the clot by cross-linking fibrin monomers. Factor IXa, together with factor VIIa, calcium, phospholipids, form a tenase complex that recruits large quantities of factor X to activate it. In turn, factor Xa together with the prothrombinase complex calcium and phospholipids, help convert prothrombin into thrombin. Thrombin then helps split fibrinogen into fibrin monomers. When factor VIII and factor IX are deficient or dysfunctional, the intrinsic pathway of the coagulation cascade cannot be appropriately activated, thus making the process of clot formation deficient. [6]

• History and Physical

Hemophilia usually presents as bleeding after minor trauma or as a spontaneous bleed. Bleeding symptoms often correlate with the degree of residual factor level, which is useful to classify hemophilia severity further. Patients with greater than 5% to 40% of factor activity of normal (mild hemophilia) often present with bleeding only after significant trauma or surgery. Spontaneous bleeding is uncommon in mild hemophilia. Typically the diagnosis is made incidentally or on routine presurgical laboratory testing. If 1% to 5% factor activity of normal is present (moderate hemophilia), bleeding usually presents after trauma, injury, dental work, or surgery. In moderate disease, recurrent joint bleed may be present in up to 25% of cases, and the diagnosis usually gets delayed. If factor activity is less than 1% of normal (severe hemophilia), bleeding often presents spontaneously. Severe hemophilia usually manifests in the first few months of life, while mild or moderate hemophilia can present later in childhood or adolescence. Recurrent frequent bleeding presents as early as in utero due to the lack of transplacental passage of both factor VIII and IX from mother to the fetus.

In cases of severe hemophilia, patients often present with internal bleeding, potentially impacting multiple organs. Joints can become painful, swollen, inflamed, warm, and have a restricted range of motion due to bleeding. The most commonly affected joints are knees, elbows, ankles, shoulders, wrist, and hips. Spontaneous joint bleed incidence typically increases with age reaching up to 60% by 65 years of age. Repetitive joint bleeds often lead to hemophilic arthropathies. Usually, hemarthroses become more frequent as physical activity increases. [11]  Brain bleeds, both intracranial and extracranial, are common, and patients can present with falls, confusion, lethargy, meningismus, and coma in severe cases. Intracranial hemorrhage is the earliest and most severe complication in the neonatal period (1% to 4% cases). [6] Extracranial bleeds such as subgaleal bleed and cephalohematoma can also be part of the initial presentation. [7]  

Patients can present with occult abdominal bleed with or without trauma, and organs like the liver, spleen, and kidneys can be involved. Typical symptoms of presentation are abdominal pain, especially over the hepatic or splenic area, abdominal distension with guarding or rigidity, melena, hematemesis, hematochezia, costovertebral angle tenderness, bladder spasms, suprapubic tenderness, or hematuria. Similarly, patients can have spontaneous or traumatic thoracic bleeds, which can present with chest pain, shortness of breath, hemoptysis, and in cases of bleeding in the throat, patients can have airway compromise. Patients with spinal hematoma can present with back pain, paresthesia, or radiculopathies. Patients with ocular bleeds like vitreous hemorrhage or hemorrhage after orbital fracture can present with vision changes and restriction of eyeball movement due to ocular muscle entrapment. Other signs of bleeding like tachycardia, tachypnea, hypotension require close attention. Bleeding in the brain, abdomen, thorax, and throat can be life-threatening. Bleeding after circumcision is also typically present in the neonatal period (incidence 0.1% to 35%), and the physicians should have a high index of suspicion. [12]  

Another characteristic presentation can be unexplained bruising when an infant begins crawling or walking or musculocutaneous hemorrhage after intramuscular vaccination. Sometimes extensive soft tissue contusions or hemorrhage can be mistaken for child abuse in young patients. The hallmark clinical presentation of both hemophilia A and B is joint (hemarthroses) and muscle bleeding, which typically presents in severe disease. Around 50% of patients with severe hemophilia will have a muscle bleed or hematoma by age 6 to 8 months and can present with compartment syndrome. The most dreadful life-threatening bleeding complications are intracranial bleeding, which is the leading cause of death in patients with hemophilia, iliopsoas muscle bleeds due to significant volume loss, and risk for hypovolemic shock, retropharyngeal bleed, and airway compromise. [13]

The diagnosis of hemophilia combines an index of suspicion due to familial history and clinical manifestation, as well as laboratory testing. Screening tests are necessary for families with an active carrier status or for those who have a family history of excessive bleeding after trauma or after surgery or known bleeding disorders in the family. Genetic testing by chorionic villous sampling or amniocentesis is available during pregnancy and is usually reserved for families with a history of hemophilia. Genetic counseling is also an option for those families who want prenatal testing for hemophilia. Pregnant females are advised to talk to their obstetricians and genetic counselors if they have one child with hemophilia and are planning to have another child. Testing for hemophilia is sometimes by obtaining a blood sample from the umbilical cord or a vein of a newborn immediately after birth, and levels of clotting factors can be checked for patients with high suspicion for hemophilia or in those patients who have a significant family history of bleeding disorders. It is important to note here that factor IX levels can be low at birth as it takes about six months for babies to reach their normal levels. Therefore umbilical cord blood samples are more accurate in finding lower levels of factor VIII, while low levels of factor IX at birth in umbilical cord blood samples do not indicate the presence of hemophilia B. 

After the prenatal period, the initial laboratory work includes but is not limited to complete blood count, prothrombin time (PT), partial thromboplastin time (PTT), and bleeding time (BT). Especially those patients who have no family history of hemophilia, findings like prolonged bleeding after circumcision or delivery or after blood draw can prompt workup of hemophilia. In both hemophilia A and B, PTT will be prolonged (intrinsic pathway disruption), whereas PT and BT will be normal. The PTT could be as prolonged as 2 to 3 times the high normal range. Once PTT is found to be prolonged, it should be followed by a mixing study. In a mixing study, the PTT should normalize if factor deficiency is suspected. After the mixing study, the next step should be factor VIII and IX assay. Hemophilia is usually the diagnosis if the factor activity is less than 40% of normal factor activity. Molecular genotyping should then be offered to confirm the diagnosis and also to help predict disease severity. [11] [6] [14]  

Also, it is now routine in most hospitals to measure factor VIII inhibitors in patients with hemophilia as some patients develop antibodies against factor VIII, which are called "inhibitors," especially following treatment with infusions of factor VIII. This fact is important as infusions of plasma-derived or recombinant factor VIII would be ineffective in patients who have antibodies against factor VIII. Inhibitors are measurable through quantitative inhibitor assays - Bethesda assay and Nijmegen assay. Original Bethesda assay was developed to standardize the measurement of inhibitors in a factor VIII neutralization assay, while in the Nijmegen assay, which is a modification of the original Bethesda method, the pH, and the protein concentration of the test mixture are further standardized. This variation makes the test mixture less prone to artifactual deterioration and improves specificity. The International Society on Thrombosis and Haemostasis recommends these assays. [15] [16]

One important bleeding disorder that often gets mixed with hemophilia is von Willebrand disease (VWD). Both hemophilia and Von Willebrand disease are bleeding disorders, but the former is caused by deficient or defective clotting factors VIII (hemophilia A) and factor IX (hemophilia B), while the latter results from deficient or defective von Willebrand factor. They are similar but have several important differences. Hemophilia is seen more in males being an X-linked disease, while von Willebrand disease is equally common in males and females due to a genetic change in chromosome 12. While bleeding in hemophilia is usually musculoskeletal, bleeding in von Willebrand disease is more mucocutaneous; this is because the von Willebrand factor targets skin and mucous membranes like linings of the nose, mouth, vagina, uterus, intestines, etc., and that is why its deficiency primarily causes nosebleeds, gum bleeds, easy bruising, heavy menstruation or heavy peri and postpartum hemorrhage. Internal bleeding is rare in von Willebrand disease, unlike hemophilia, Von Willebrand disease is usually diagnosed by quantitative tests like checking von Willebrand factor antigen levels and factor VIII clotting activity and by qualitative tests like checking ristocetin cofactor and von Willebrand factor multimers to measure how well the von Willebrand factor works. [14] [17]

Healthcare providers are also often challenged when patients with hemophilia present with signs and symptoms of suspected internal bleeding. It becomes crucial for the healthcare team to evaluate them and order tests in a timely fashion to rule out life-threatening bleeds like intracranial bleeds or abdominal bleeds. When patients present with altered mental status, confusion, cognitive dysfunctions, or multiple falls, the CT scan of the head or MRI of the brain is ordered to rule out intracranial bleed, this factor is crucial, especially in neonates, infants, and during early childhood, as these patients may not be able to provide a detailed history. Sometimes adults with hemophilia may present with unusual symptoms like cognitive dysfunction due to frequent but silent cerebral microbleeds and require MRI of the brain to evaluate these microbleeds. [18] [19]  Patients with recurrent joint bleeds can benefit from point-of-care ultrasonography of joints to monitor the progress of hemophilic arthropathies. [20]  Abdominal or thoracic bleeds can undergo evaluation with a CT scan or MRI of the chest and abdomen. [21]

• Treatment / Management

The hemophilia treatment strategy is primarily divided into two categories - management of acute bleeding and prophylaxis.

Management of Acute Bleeding in Hemophilia 

The fundamental concept of management of a diagnosed or confirmed acute bleeding in hemophilia is to achieve quick and aggressive hemostasis, preferably within two hours of the onset of symptoms and correction of coagulopathy, but these measures should not be delayed even if diagnostic tests are pending or if physical symptoms are not present. Patients require hospitalization, and guidelines from the World Federation of Hemophilia should be followed for the management of acute bleed. Usually, patients can tell when a bleeding episode is about to occur by the presence of a tingling sensation or “aura,” but relevant and quick history should be obtained from available sources if patients can not communicate.

Any patient with hemophilia who presents with severe acute bleeding episode requires quick recognition of the location and severity of the bleed; this must be followed by immediate replacement with high-dose clotting factor concentrate (CFC) with factor VIII or IX. Doses of factor concentrate should be 50 IU/kg body weight factor VIII or 100 to 120 IU/kg factor IX. If factor IX concentrate is not available, then 70 to 80 IU/kg of prothrombin complex concentrate can be infused. Some patients may require urgent surgery or a procedure in cases of intracranial bleed, airway compromise from throat bleed or neck hematoma, large abdominal or thoracic bleeds, or compartment syndrome with large muscle hematomas. However, replacement with high-dose CFC must happen first or simultaneously with any planned surgery or procedure except when a patient requires cardiopulmonary resuscitation (CPR), where CPR supersedes high-dose CFC replacement.

Appropriate imaging studies should be done to determine bleeding sites, followed by appropriate specialty referrals based on the location and severity of the bleed. Even if the bleeding slows down or stops, high-dose CFC should still be given as required to allow healing. Frequent measurements of factor levels must be done to make sure that desired levels are maintained. Upon achieving hemostasis and once the coagulopathy is corrected, the workup for hemorrhage should begin. While performing pain management, one should avoid acetylsalicylic acid (ASA) and non-steroidal anti-inflammatory drugs (NSAIDs) due to their effects on platelet function and risk for increased bleeding. Acetaminophen and certain COX-2 inhibitors are safe to use. Also, intramuscular injections should be avoided if possible. [14] [22]

Prophylaxis in Hemophilia 

Apart from treating acute bleeding, another strategy of treatment in patients with hemophilia is prophylaxis. Prophylactic treatment has several advantages. It can reduce hemarthroses episodes and thereby reduce hemophilic arthropathy and the need for corrective joint surgeries. Prophylactic treatment can also reduce the frequency of cerebral and muscle bleeds and reduce the need for hospitalizations. It helps improve the quality of life for patients by allowing them to take less time off work and less frequent monitoring. Also, in a study from Bremen and Munich on low levels of prophylactic treatment, it has been suggested that the development of inhibitor risk is reducible. This study only found one low responding inhibitor in 40 children with severe hemophilia A followed up for a minimum of 40 exposures. [23]  According to the World Federation of Hemophilia guidelines, prophylaxis is further categorized as primary or secondary and continuous or intermittent. Prophylaxis is denoted as continuous if it initiates with the intent to treat for 52 weeks in a year and is accomplished for at least 45 weeks of that year.

The intermittent prophylaxis regimen does not exceed more than 45 weeks in a year. On-demand or episodic treatment is indicated at the time of clinically evident bleeding. Continuous prophylaxis can further subdivide into (1) primary if the treatment initiates before the onset of osteochondral joint disease, before 3 years of age and before the two clinically evident large joint bleeds, (2) secondary if the treatment starts after two or more major bleeds into a large joint and before the onset of osteochondral joint disease and (3) tertiary if the treatment starts after the onset of documented osteochondral joint disease. The optimal regimen remains to be defined, but two prophylactic protocols currently used are the Malmo protocol and the Utrecht protocol. A frequent practice is to initiate prophylactic treatment once or twice per week and increase the frequency until a full primary prophylactic dose is reached, before the onset of joint bleeding or other serious bleeds at 12-18 months of age. [14] [24]

Factor VIII Dosing Calculations, Schedules, and Target Levels

Ideally, the goal of dosing is to maintain the factor levels above 1% to 2%, but dosing schedules vary and are dependent on factor deficiency and the patient, their bleeding rate, and ease of IV access. In hemophilia A, factor VIII infusion of 25 to 40 units/kg of body weight three times per weak per Malmo protocol or 15 to 30 units/kg three times per week per Utrecht protocol can be used.  In hemophilia B, factor IX infusion of 25 to 40 units/kg of body weight two times per week per Malmo protocol or 15 to 30 units/kg two times per week per Utrecht protocol can be used. The dose of factor VIII is calculated by body weight in kilograms and multiplying it with the desired increase in factor VIII and 0.5 units/kg. Factor levels are usually measured 15 minutes after the infusion to verify the calculated dose. Typically, 1 unit/kg factor VIII infusion increases plasma levels of factor VIII by 2% with a half-life of about 8 to 12 hours, and hence, the infusion dose is calculated accordingly. Infusion is done slowly at a rate of less than 3 ml/minute in adults and less than 100 units/minute in young children. Factor VIII target levels are dependent on the location and severity of bleeding. In mild hemorrhages, levels are maintained at 30%, in moderate hemorrhages, levels are maintained at 50%, and in severe life-threatening hemorrhages, levels are maintained at 80% to 90%, and after stabilizing the bleeding, levels are maintained at 40% to 50% at least for 7 to 10 days. Due to its half-life of 8 to 12 hours, the second dose of factor VIII is given 8 to 12 hours after the first dose and is usually half of the first calculated dose. Mild hemorrhages require 1 to 3 doses, while severe hemorrhages require many more doses with the goal of maintaining levels at 40% to 50% for 7 to 10 days at least. Occasionally continuous infusions are also required for very severe hemorrhage or major surgery.  The decision to stop prophylaxis is dependent on patients, their symptoms, and their concerns. Some patients may want to switch to less frequent dosing schedules or may want to go off prophylaxis and monitor symptoms. [25] [26]

Plasma-derived Versus Recombinant Factor VIII

In the 1950s, fresh frozen plasma was first used as a replacement factor in patients with hemophilia, followed by cryoprecipitates in the 1960s. In the 1970s, lyophilized factor VIII was derived from plasma and brought a huge change in the treatment of patients allowing them to gets home infusion therapy. However, in the 1980s, many patients with hemophilia were affected by contaminated factor concentrates, and 60% to 70% of patients got infected with HIV. Almost 100% of patients got infected with hepatitis C. This tragedy prompted more research to make plasma-derived factor concentrate safer. Eventually, cloning of the gene for factor VIII occurred in 1984, and recombinant factor VIII concentrate became available in 1992.

The availability of recombinant factor VIII, along with viral inactivation and better screening technology, made factor products safer and revolutionized the treatment of hemophilia. Despite the availability of plasma-derived factor concentrates, about 75% of patients with hemophilia worldwide receive recombinant factor VIII products since they are much safer. Today, many different recombinant factor VIII products are available, including first, second, third, and fourth-generation with and without extended half-life. In developed countries, third-generation recombinant factor VIII products are now most commonly used as their production does not contain any animal or human products. Also, the focus is now shifting towards third-generation recombinant products with an extended half-life.

Extended half-life products have made it possible to have fewer scheduled infusions, with research underway to produce factor VIII products with PEGylation and fusing factor VIII with Fc receptor, which has led to products with longer half-lives. FDA has recently approved PEGYlated factor VIII and Fc-factor VIII fusion product, with the latter having a half-life of 19.7 hours, the longest among all the currently available products. Even a modest increase in the half-life of factor VIII can reduce the frequency of infusions and can significantly improve the quality of life for the patients. More and more research is now being done to improve the half-lives to decrease the frequency of infusions and decrease the immunogenicity of the factor products to lessen the prevalence of the development of inhibitors. [27] [28]

Other Pharmacological Options

Apart from plasma-derived and recombinant coagulation factor concentrates, other agents are also useful in the treatment of hemophilia. They are desmopressin, tranexamic acid, and epsilon aminocaproic acid. 

1. Desmopressin (DDAVP) -  Desmopressin is a synthetic vasopressin analog. It works by increasing endogenous factor VIII plasma concentrations by 3 to 5 times by inducing the release of von Willebrand factor (VWF). It has utility in the treatment of patients with mild or moderate hemophilia A instead of using a factor concentrate and thereby reducing the expense and decreasing the risk of development of inhibitors. It is mainly useful in the prevention or treatment of bleeding in patients who are carriers of hemophilia. It has no value in hemophilia B as it does not affect levels of factor IX. Desmopressin is much cheaper than factor concentrates, and it carries no risk of viral infection transmission. It can be used subcutaneously, which is the most common route of administration but can also be given intravenously and intranasally. It should be avoided in pre-eclampsia and eclampsia as those patients already have high levels of von Willebrand factor. Also, due to its antidiuretic property, hyponatremia and water retention can occur. Therefore its use is contraindicated in children less than two years of age who can be at risk of developing seizures due to cerebral edema secondary to water retention and should also be used carefully in adults with a history of congestive heart failure or cardiovascular disease. [29] [30]

2. Tranexamic acid and epsilon aminocaproic acid -  Both tranexamic acid and epsilon aminocaproic acid are antifibrinolytic agents and promote clot stability. Epsilon aminocaproic acid is less commonly used as it is more toxic, has a shorter half-life, and is less potent. They cannot be used as a standalone treatment for musculoskeletal bleeding but are useful in preventing mucocutaneous bleeds like epistaxis, heavy menstruation, or in the setting of dental surgery except in patients with hematuria as it may prevent the dissolution of clots in the urine and may cause obstructive uropathy. Also, in patients undergoing thoracic surgery, it may result in the development of insoluble hematomas and should not be used. [31]

Novel Therapies in Hemophilia 

1) Gene Therapy 

Cloning of the gene not only allowed the production of recombinant factors but also promoted gene therapy efforts to cure the disease. Due to the monogenic nature of inheritance and because even a small amount of increase in clotting factor activity can significantly reduce bleeding incidences and improve quality of life, hemophilia remains an optimal target for gene therapy, and early phase I and II trials have shown success. The biggest issue right now is that gene therapy still has certain limitations when used in patients with liver disease, pediatric populations, and patients who have pre-existing antibodies to factor, and further research and trials are underway to make it more broadly applicable. [32]

2) Monoclonal Antibodies

Apart from gene therapy, the development and application of monoclonal antibodies, like emicizumab and concizumab, for the treatment of hemophilia have generated a lot of excitement. Emicizumab is a monoclonal antibody that mimics the function of activated factor VIII molecule but does not structurally or immunologically resemble factor VIII and, therefore, is not affected by inhibitors. Also, it has excellent safety and tolerability, can be administered subcutaneously, has a longer half-life of 4 to 5 weeks, and has led to a significantly decreased annualized bleeding rate with the administration of a higher dose. Also, no anti-drug antibodies were detected during the studies. Still, more studies are ongoing to study potential side effects and the impact of treatment in patients suspected of having poor outcomes. Monoclonal antibodies have the potential to revolutionize the treatment of hemophilia, and therefore, emicizumab received breakthrough treatment designation. [33]

Management of Joint Bleeding in Hemophilia

The most common complication of hemophilia is joint bleed, which can cause significant morbidity and requires early prevention and treatment before chronic degenerative changes set in. Management of joint bleeds requires a comprehensive strategy with the primary focus being the prevention of bleed, and prophylaxis is the recommended first-choice treatment by the World Health Organization and World Federation of Hemophilia. Primary prophylaxis is given to patients with severe hemophilia before the joint bleed, while secondary prophylaxis is given after the first joint bleed but before the onset of joint damage. Prophylaxis is usually started at an early age to prevent and reduce the risk of joint bleed and the development of hemophilic arthropathy. Dosing is individualized and changed according to the severity of the bleed. In acute bleeding episodes, it is important to achieve hemostasis quickly by giving on-demand factor infusion as early as possible. Patients who have chronic synovitis and recurring joint bleeds can benefit from short-term treatment courses of secondary prophylaxis for about 6 to 8 weeks.

Apart from on-demand and prophylactic treatment, pain management remains the most important aspect of controlling the patient's symptoms. ASA and NSAIDs should be avoided, and milder opioids or acetaminophen are options for pain control. Occasionally for chronic synovitis, intraarticular steroid injections can be given. Rest, ice application, compression, and elevation are therapeutic choices for patients with minor joint bleeds. Immobilization of painful joints should occur only for the necessary duration as prolonged immobilization can lead to muscle atrophy and limitation of range of motion. Early initiation of physical therapy and exercise program are critical for reducing swelling and pain, maintaining strength and range of motion, and prevent further injury by gait training patients. It also plays a huge part in preventing bleeding and also rehabilitating patients after surgery or those who have severe joint damage. In some cases, joint aspiration may be necessary following failed response to factor replacement after 48 to 72 hours or where bleeding is in a major joint like the hip where the pain is uncontrollable, but in general, it is not a recommended treatment. If aspirating a joint, then factor replacement should be done simultaneously, and the utmost precautions should be taken to avoid the incidence of septic arthritis.

Surgery is usually reserved for refractory cases where conservative management has failed, or irreversible joint destruction has occurred. Different modalities like synovectomy, joint debridement, joint arthroplasty, and joint fusion, known as arthrodesis, can be employed on a case-by-case basis. Despite the availability of many treatment modalities, hemophilic arthropathy remains the single most common complication in patients affecting their quality of life. [34]

Pain Management in Hemophilia

Pain in patients with hemophilia can be acute or chronic. It could be pain from joint or muscle bleeds, from repeated attempts at venous access, from hemophilic arthropathy due to chronic degenerative joint disease, or after surgery/procedure. It is important to know the cause of pain to decide the management. Usually, for pain caused by repeated attempts at venous access, no pain medications are necessary, especially in adults, but in children, the application of local anesthetic spray or cream can help at the site of IV access. For acute joint or muscle bleeds, rest, compression, elevation, cold packs, immobilization, crutches, splints, braces, or wheelchairs can be useful as adjunctive therapies. Intramuscular injections of pain medications or steroids should be avoided. Ideally, the first-choice drug for pain control is acetaminophen or paracetamol. If those are not effective, then COX-2 inhibitors such as celecoxib, meloxicam, etc., can be used. If COX-2 inhibitors are not preferred, then the combination of acetaminophen or paracetamol with low-dose opioids such as codeine, tramadol, hydrocodone, or morphine can be used. These medications can be given 3 to 4 times per day, along with other adjunctive therapies to control the pain. Products containing ASA or NSAIDs should be avoided. Sometimes, persistent pain may require corrective surgery or referral to a pain management team. [35]

Importance Of Physical Activity in Hemophilia

Physical activity is of utmost importance in patients with hemophilia to ensure physical fitness, muscle strengthening, maintaining healthy body weight, bone density, and proper muscle development. Preventive physical therapy and therapy after a joint bleed or surgery are extremely crucial. The choice of physical activity is usually determined by the patient's ability, interests, and available resources. Contact sports like soccer, rugby, boxing, etc., should be avoided. High-velocity sports like racing, skiing should be avoided too. Noncontact sports such as swimming, golf, badminton, cycling, table tennis, walking, etc., should be encouraged. Organized sports activities are the recommended option, as they can have appropriate supervision, and protective gear and equipment are available. Also, before indulging in any physical activity, the patient should talk to a therapist or a professional to discuss what kind of protective gear they should wear to protect the problem joints, to know whether they require any additional physical training before doing the activity, and also to discuss whether they need any prophylactic treatment to get their factor levels higher and prevent bleeding. [36] [37]

Hemophilia Treatment Cost

With the improved life expectancy due to the availability of early diagnosis and improved treatment options for acute bleeding and prophylaxis both, children born with hemophilia today are now expected to have a normal life expectancy in developed countries. But this has also increased the cost significantly as patients with hemophilia are not only living longer, but they also require more frequent infusions due to low half-lives of factor products and the development of inhibitors in about 25% to 30% of patients. The average cost of treatment per year in the US is about $150000 to $300000, while in Europe, it is close to 77000 euros to 112000 euros, and those patients who have inhibitors can have 3.3 times the cost compared to patients who do not have inhibitors. Also, apart from treatment, there are additional costs for hospitalizations, laboratory tests, office visits, and indirect costs for decreased productivity and missing work or school. Plus, the disease takes a heavy emotional and physical toll on patients and their caregivers by reducing their quality of life, causing them pain and suffering, and increasing their intangible costs. The disease that was formerly fatal has now become a chronic well-managed problem. Still, there is a tremendous need for understanding the proper utilization of healthcare resources and the education of patients regarding their clinical condition and compliance with treatment. [28] [38] [39]

• Differential Diagnosis

Other conditions can also present similarly with bleeding after minor trauma or spontaneous bleeds and require exclusion before confirming the diagnosis of hemophilia. Some of these conditions include von Willebrand disease, scurvy, diseases of platelet dysfunction, deficiency of other coagulation factors like V, VII, X, or fibrinogen, Ehlers-Danlos syndrome, Fabry disease, disseminated intravascular coagulation, and child abuse. In von Willebrand disease, bleeding symptoms can be similar to mild hemophilia, but patients with von Willebrand disease have more mucosal bleeding compared to musculoskeletal bleeding seen in hemophilia. Von Willebrand disease is diagnosed by checking for von Willebrand factor antigen or von Willebrand factor multimers. [40]  Similarly, in scurvy, Ehlers-Danlos syndrome, and Fabry disease; also, the bleeding is usually mucosal, unlike hemophilia, where it is musculoskeletal. In scurvy, there is a deficiency of vitamin C. [41]  In Ehlers-Danlos syndrome, the skin is hyperextensible, and joints are hypermobile. The diagnosis is usually through clinical features, genetic testing, and tissue biopsy. [42]  Similarly, in Fabry disease, patients may also have other organs being affected, including kidneys and heart, and have skin lesions called angiokeratomas. They also have pain in the extremities. Fabry disease is usually diagnosed with clinical findings and genetic testing. [43]  In cases of platelet dysfunction disorders, bleeding is usually mucocutaneous, unlike hemophilia. Usually, these disorders are diagnosed by platelet aggregation studies or platelet electron microscopy. [44]  In the deficiency of other coagulation factors, musculoskeletal bleeding is uncommon. In fact, sometimes thrombosis can occur, especially in patients with factor VII or fibrinogen deficiency or in patients with combined factor V and VIII deficiency. Specific coagulation factor assays usually confirm the diagnosis. Disseminated intravascular coagulation (DIC) that mimics hemophilia is hard to differentiate, but usually, there is an underlying condition in DIC, for example, acute promyelocytic leukemia. Diagnosis is usually carried out by blood tests that show decreased platelet count and the absence of factor VIII autoantibodies. Child abuse can sometimes be misidentified and confused with hemophilia, and it is essential to find inconsistencies in the history of how trauma has occurred. Other signs of malnourishment require vigilance, and x-rays may reveal evidence of fractures of different ages. [45] [46]

The life expectancy of people who had severe hemophilia in the 1950s and 1960s before the development of factor concentrates was only 11 years. Most people who had severe hemophilia died in early childhood or adolescence from intracranial bleeds or bleeding inside the vital organs. In 1964, Judith Pool found the fraction cryoprecipitate from the plasma, which had large quantities of factor VIII concentrate, which significantly improved hemophilia treatment. Before that, patients with hemophilia could only have treatment with whole blood or fresh plasma, which lacked sufficient quantities of factor VIII or IX proteins. In the 1970s, lyophilized plasma concentrates of coagulation factors became available, and this improved treatment significantly.

Primary prophylaxis began in Sweden before being adopted by other countries, which ended up preventing major bleeding episodes and complications of arthropathies. In 1977, researchers discovered desmopressin. With that, patients were able to get a better, safer, and relatively inexpensive option for treatment, and risks of blood-borne infections from repeated use of plasma-derived products were minimized. After patients with severe hemophilia got infected with HIV and hepatitis C from contaminated coagulation factors in the 1980s, methods to screen and inactivate viruses in blood were developed, and this improved the safety of plasma-derived products significantly. Eventually, the advancement in DNA technology allowed the industrial production of recombinant factor VIII and IX.

The widespread availability of replacement therapy to prevent and treat active bleeding, advancement in viral inactivation techniques, management of blood-borne infections through surveillance, and availability of newer treatment options for hepatitis C and HIV treatment have significantly improved the lifestyle of patients with hemophilia. Today, life expectancy for patients is almost the same as the general population in developed countries, provided those patients respond well to the treatment and do not have other health conditions. But in developing countries, where healthcare access and treatment resources are scarce, the mortality rate remains almost twice that of the general population. [47] [48] [49]

• Complications

Development of inhibitors and the role of immune tolerance induction and monoclonal antibodies

The major complication of therapy in patients with hemophilia is the development of inhibitors. [1] Inhibitors are alloantibodies (IgG) directed against factor VIII and IX that neutralizes its action. It is the most severe treatment-related complication of hemophilia. The presence of inhibitors should be suspected if bleeding fails to stop after infusion of clotting factors in a patient who was responsive in the past. Inhibitors make the half-life of infused factor concentrate even shorter and thereby decrease their efficiency. Inhibitors are more frequent in hemophilia A than hemophilia B, as well as in severe hemophilia with an incidence of 20% to 30% compared to mild hemophilia with an incidence of 5% to 10%. The median age of inhibitor development is three years or less in severe hemophilia, while it is closer to 30 years in mild or moderate hemophilia. Inhibitors in mild or moderate hemophilia predominantly cause bleeding from mucocutaneous sites. Confirmation of the presence of an inhibitor is via the Nijmegen-modified Bethesda assay.

Children and adults should receive frequent screening for the development of inhibitors. For children, there should be screening once every five exposure days until 20 exposure days, every ten exposure days between 21 and 50 exposure days, at least two times a year until 150 exposure days, before surgery, or when switching to a new factor concentrate. They should be measured in all patients who have received intensive treatment lasting more than five days and within four weeks of the last infusion. If post-operative bleeding occurs and response to on-demand therapy is not optimal, then the presence of inhibitors should be assessed. Inhibitors are further sub-classified as low responding and high responding. High responding inhibitors usually persist in time. If not treated for an extended period, the levels may fall or become undetectable, but when infusing the factor concentrate again, they will become active and may render the infusion ineffective. Titers might decrease, but when the patient is exposed again to factor products, titers may rise within 3 to 5 days of the exposure. Low responding titer inhibitors are usually transient, disappear by six months, and would not reappear after the patient is re-exposed to factor products.

Treatment of acute bleeding episodes in patients with the presence of inhibitors starts with a consultation with the hemophilia center as soon as possible. Some treatment modalities include but are not limited to a higher dose of factor, porcine factor VIII, recombinant factor VII activated, and prothrombin factor complex concentrates. Eradication of inhibitors in a patient with hemophilia A is also possible by immune tolerance induction. [14]  So far, immune-tolerance induction has been found to be a proven therapy to eradicate inhibitors. This protocol involves repeated and frequent infusion of factor VIII. Patients who are getting immune-tolerance therapy typically get daily doses of factor concentrate over weeks or even years in some cases. Some patients may also be given immunosuppressive medications while on treatment, which can make them more prone to infections. The goal of this therapy is to ensure that the body tolerates the factor infusions and does not mount an immune response by downregulating an already established antibody response. Immune-tolerance induction can remove inhibitors in about 70% of patients with hemophilia A and 30% of patients with hemophilia B. [50]  Another promising therapy is monoclonal antibodies, which are now being studied and have shown a lot of promise in the treatment of patients with inhibitors. This potential benefit is because monoclonal antibodies like emicizumab mimic the function of activated factor VIII molecule but do not structurally or immunologically resemble factor VIII and, therefore, are not affected by inhibitors. [33]

Musculoskeletal Complications

Another critical complication of hemophilia is hemophilic arthropathies from repeated musculoskeletal bleeding. About 90% of patients with severe hemophilia who have had repeated musculoskeletal bleeds end up having chronic degenerative changes in major joints like ankles, knees, and elbows in their 20s and 30s. The only way to prevent these arthropathies is to prevent spontaneous intraarticular hemorrhage by providing prophylactic treatment; however, subclinical hemorrhages can still occur despite prophylactic treatment. Management of joint bleeds has been discussed extensively in the treatment section. [51]

Pseudotumors

Pseudotumor is a life, and limb-threatening condition due to inadequately treated soft tissue bleeds, usually in muscles adjacent to the bones. It is most commonly seen in long bones or pelvis. If not treated timely and adequately, pseudotumors can rapidly enlarge and lead to neurovascular compromise by pressure on adjacent structures. It can also cause pathologic fractures and create fistulas through the skin. Clinical examination and imaging studies are essential in diagnosis. Small pseudotumors can be monitored, while larger ones can receive aspiration or surgical ablation. Factor concentrate infusion is necessary and should occur for at least six weeks, followed by repeat imaging to document a decrease in the size. Large pseudotumors that have failed conservative management and those that are rapidly expanding may require limb amputations. Abdominal pseudotumors require surgery as soon as possible. [52]

Fractures can occur in patients with hemophilic arthropathy. Immediate treatment of a fracture is replacement with factor concentrate to raise the levels to almost 50% and maintain them at that level for at least 3 to 5 days. Surgical management depends on the location and severity of the fracture, and splints or external fixators may be necessary. Immobilization for a necessary duration with early initiation of physical therapy is crucial. [53]

Blood-borne Infection-related Complications

In the 1980s, factor concentrates got contaminated with viruses like HIV and HCV, and patients who received those got infected with HIV and hepatitis C. This resulted in high mortality rates in patients with hemophilia in the 1980s and early 1990s. Today, many studies show that HIV and HCV transmission through factor concentrate has been almost eliminated due to careful selection of donors, screening techniques, viral elimination process during manufacturing, and advancement in diagnostic procedures to detect these viruses early. Higher usage of recombinant factors has dramatically decreased the risk of infection. However, new challenges from non-lipid enveloped viruses and prion diseases are emerging. Also, currently available anti-HIV medications are all safe for use in patients, with no contraindications. For patients with hepatitis C and hemophilia, pegylated interferon and ribavirin are the treatment. [51]

• Pearls and Other Issues

Patients with hemophilia should pay regular visits to their doctors and discuss any episodes of bleeding they may encounter. Furthermore, they should avoid taking any over-the-counter painkillers like naproxen or aspirin that may increase their risk of bleeding. They should also take good care of their oral hygiene and visit the dentist regularly.

• Enhancing Healthcare Team Outcomes

The patient should be treated in a comprehensive treatment center where an interprofessional approach between doctors (chronic pain specialist, geneticist, hematologist, immunologist, etc.), nurses, musculoskeletal experts, laboratory specialists, pharmacists, and psychology experts are available at all times to the patients and their families.

Patient education is vital in improving the long-term prognosis of patients, reducing mortality rates, and improving their lifestyles. Ideally, early detection, adequate follow-up, and timely treatment all play a significant part in improving patients' prognosis. Any patient with hemophilia should receive a hematology referral and require close follow-up by a specialized hemophilia center or service. Education should be provided to the patients to monitor their symptoms and seek early treatment.

Children with hemophilia should be vaccinated, even with intramuscularly administered vaccines. The vaccination is best with a 23 gauge needle with prior ice pack application to the area for 5 minutes and soon after. Factor replacement is given but not on the same day. Appropriate dental care should be encouraged for all children with at least two times per day dental cleaning with flossing and a medium texture bristles toothbrush and age-appropriate toothpaste with fluoride. Some dental procedures might require the prophylactic application of factor concentrates or other prophylactic modalities. Suggestions are that any major dental surgeries should occur within a hemophilia treatment center. [54]  Physical activity is a recommendation in all children with hemophilia. The activity of choice should reflect patients' interests. Non-contact sports (swimming, walking, golf, badminton, archery, cycling, etc.) are always encouraged. Contact sports (soccer, rugby, boxing, etc.) and high-velocity sports are permissible if the patient is on good prophylaxis to cover these sports. [55] [56] [57] [58] With an increase in the complexity of hemophilia treatment, a shared decision-making approach should be taken involving patients in their care, and all the tools should be provided to the patients to facilitate informed decision-making. [59]  

It is also crucial to make sure that patients are compliant with prophylactic treatment schedules to reduce the incidence of joint bleeds and improve the quality of life. There were studies to measure adherence to prophylaxis in children and adults, and some of the studies found that although the rate of adherence is improving with better patient education and more awareness among the patients, about 40% of patients still find it difficult in adhering to prophylactic treatments over a long period. Adherence is usually quantifiable by the number of doses of medications given compared with the number of doses prescribed. The target goal of adherence should be at least 75% to 80% of medication doses. The pharmacist should carefully examine the patient's medication profile frequently and collaborate with the treating clinicians regarding any necessary changes to either agents or dose regimens. The healthcare team should try to discover the factors that could be affecting adherence to prophylaxis for patients and try to address them comprehensively to improve compliance and reduce long-term complications and improve physical activity in patients. [60] [61] [62]

Patients should be followed up for at least every six months by all core team members to coordinate care and supervise at-home treatment regimens. Nursing staff can verify therapeutic compliance, serve as an entry point to the healthcare team, and answer patient questions, reporting any concerns to the rest of the team. Home therapies should be established promptly after diagnoses and as soon as families have the required education and training and feel comfortable with hemophilia management since it provides the most immediate access to early treatment and decreases overall pain, dysfunction, disability, and hospital admissions. [7] [14] [63]

Hemophilia requires a complete interprofessional effort at an even higher level than most other conditions; when executed properly, this approach can lead to a higher quality of life and life expectancy. [Level 5]

• Review Questions
• Access free multiple choice questions on this topic.
• Comment on this article.

Disclosure: Parth Mehta declares no relevant financial relationships with ineligible companies.

Disclosure: Anil Kumar Reddy Reddivari declares no relevant financial relationships with ineligible companies.

This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.

• Cite this Page Mehta P, Reddivari AKR. Hemophilia. [Updated 2023 Jun 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-.

In this Page

Bulk download.

• Bulk download StatPearls data from FTP

Related information

• PMC PubMed Central citations
• PubMed Links to PubMed

Similar articles in PubMed

• Acquired Hemophilia. [StatPearls. 2024] Acquired Hemophilia. Haider MZ, Anwer F. StatPearls. 2024 Jan
• Hemophilia A. [StatPearls. 2024] Hemophilia A. Salen P, Babiker HM. StatPearls. 2024 Jan
• Review Hemophilia A: Dental considerations and management. [J Int Soc Prev Community Dent....] Review Hemophilia A: Dental considerations and management. Shastry SP, Kaul R, Baroudi K, Umar D. J Int Soc Prev Community Dent. 2014 Dec; 4(Suppl 3):S147-52.
• [Haemophilia--then and now]. [Sydsven Medicinhist Sallsk Ars...] [Haemophilia--then and now]. Nilsson IM. Sydsven Medicinhist Sallsk Arsskr. 1994; 31:33-52.
• Review Comprehensive care for hemophilia and other inherited bleeding disorders. [Transfus Apher Sci. 2019] Review Comprehensive care for hemophilia and other inherited bleeding disorders. Page D. Transfus Apher Sci. 2019 Oct; 58(5):565-568. Epub 2019 Aug 6.

Recent Activity

• Hemophilia - StatPearls Hemophilia - StatPearls

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Connect with NLM

National Library of Medicine 8600 Rockville Pike Bethesda, MD 20894

Web Policies FOIA HHS Vulnerability Disclosure

Help Accessibility Careers

Hemophilia B

Mar 19, 2019

700 likes | 1.91k Views

Hemophilia B. Bijan Keikhaei, Ahvaz Jundishapur University of Medical Sciences. Hemophilia B. Hemophilia B, or Christmas disease, is an inherited, X-linked, recessive disorder that results in deficiency of functional plasma coagulation factor IX.

Share Presentation

• severe pain
• approximately 8
• joint hemorrhage hemarthrosis
• factor replacement therapy protocols

Presentation Transcript

Hemophilia B Bijan Keikhaei, Ahvaz Jundishapur University of Medical Sciences

Hemophilia B • Hemophilia B, or Christmas disease, is an inherited, X-linked, recessive disorder that results in deficiency of functional plasma coagulation factor IX. • As many as 1/3 of all cases are the result of spontaneous mutation. • Hemophilia B occurs in about one in 25,000 male births and • affects about 3,300 people in the United States.

Severity of Hemophilia B • The normal range of FVIII and FIX is between 50% and 150%. Hemophilia severity is classified as follows: • Hemophilia B constitutes about 20% of hemophilia cases, about 50% of cases→ factor IX <l%= Severe • 30% of cases→ factor IX <l-5%= Moderate • 20 %of cases→ factor IX >6-40%= Mild

Hemophilia B-Inheritance

Women with Hemophilia B There are circumstances, however, when females can experience bleeding symptoms. Symptomatic carriers Daughters of a father with hemophilia and a carrier mother Turner’s syndrome

Hemophilia B-Signs & Symptoms Neonates: Prolongedbleeding and/or severe hematoma following procedures such as circumcision, phlebotomy, and/or immunizations; intracranial hemorrhage. Toddler: Trauma-related soft-tissue hemorrhage; oral bleeding during teething

Hemophilia B-Signs & Symptoms Children and Adults: Hemarthrosis and hematomas with increasing physical activity; chronic arthropathy (late complication); traumatic intracranial hemorrhage (life threatening)

Diagnosis 1-Personal history of bleeding. 2-Family history of bleeding and its inheritance pattern. 3-Laboratory testing. Usually, the activated partial thromboplastin time (aPTT) is prolonged; however, a normal aPTT does not exclude mild or even moderate hemophilia because of the relative insensitivity of the test. The aPTT is significantly prolonged in severe hemophilia. FVIII deficiency or hemophilia A can be diagnosed at birth because newborns should have normal levels of FVIII. In contrast, FIX levels are low during the newborn period and may take 6 months to reach normal levels. The diagnosis of mild FIX deficient hemophilia, therefore, may be more difficult in the newborn period.

Sites of bleeding in hemophilia Life-threatening Intracranial Neck/throat Gastrointestinal Serious Joints (Hemarthrosis) Muscles, especially deep compartments (iliopsoas,calf, and forearm) Mucous membranes in the mouth, gums, nose, and genitourinary tract

Joint hemorrhage (Hemarthrosis) A joint bleed is defined as an episode characterized by rapid loss of range of motion as compared with baseline that is associated with any combination of the following: pain or an unusual sensation in the joint, palpable swelling and warmth of the skin over the joint. The onset of bleeding in joints is frequently described by patients as a tingling sensation and tightness within the joint. This “aura” precedes the appearance of clinical signs.

Joint hemorrhage (Hemarthrosis) A target joint is a joint in which 3 or more spontaneous bleeds have occurred within a consecutive 6-month period.

Arthrocentesis Arthrocentesis (removal of blood from a joint) may be considered in the following situations: a bleeding, tense, and painful joint, which shows no improvement 24 hr after conservative Treatment . evidence of neurovascular compromise of the limb unusual increase in local or systemic temperature and other evidence of infection (septic arthritis). When necessary, arthrocentesis should be performed under factor levels of at least 30– 50 IU Dl for 48–72 hr.

Bleeds requiring admission Suspected intracranial haemorrhage. Bleeding into neck/throat. Forearm/calf bleed with suspicion or evidence of compartment syndrome. Bleeding into hip or inguinal area, suspected iliopsoas haemorrhage. Undiagnosed abdominal pain. Persistent hematuria. Bleeds causing severe pain.

General Measures - Joint and Muscle Bleeds R = Rest (in position of comfort) I = Ice (Cold pack to reduce bleeding and pain) C = gentle compression bandage E = Elevation S = splint

Treatment Mild hemorrhages (ie, early Hemarthrosis, epistaxis, gingival bleeding): Maintain a FIX level of 30% Major hemorrhages (ie, Hemarthrosis or muscle bleeds with pain and swelling, prophylaxis after head trauma with negative findings on examination): Maintain a FIX level of 50% Life-threatening bleeding episodes (ie, major trauma or surgery, advanced or recurrent Hemarthrosis): Maintain a FIX level of 80-90%. Plasma levels are maintained above 40-50% for a minimum of 7-10 days .

Recommended clotting factor dosage

Analgesia Paracetamol/codeine is sufficient in most cases, however morphine, tramadol can be used for severe pain . Splinting/immobilisation is an effective adjunct for reducing pain . Do not use products containing aspirin or NSAIDS (eg. ibuprofen, diclofenac).

Antifibrinolytic Therapy (tranexamic acid), Adjunctive management Reduces breakdown of blood clots and is effective for treating and preventing recurrence of mouth bleeds and epistaxis. Contraindicated for treatment of haematuria.  Dose of tranexamic acid 25mg/kg/dose (max:1.5g/dose) tds orally for 5-7 days. Tranexamic acid should not be given to patients with FIX deficiency receiving prothrombin complex concentrates, as this will exacerbate the risk of thromboembolism.

Antifibrinolytic Therapy (tranexamic acid) Weight (kg) Tranexamic acid <20 Kg 250 mg tds 20 – 30 Kg 500 mg tds 30 – 40 Kg 750 mg tds > 40 Kg 1 g tds

Definitions of factor replacement therapy protocols Protocol Definition Episodic Treatment given at the time of clinically evident bleeding Continuous prophylaxis :primary,Secondary,Tertiary,Intermittant

Surgery and invasive procedures Preoperative assessment should include inhibitor screening and inhibitor assay, particularly if the recovery of the replaced factor is significantly less than expected. Surgery should be scheduled early in the week and early in the day . Adequate quantities of clotting factor concentrates. Infusion of factor concentrates/hemostatic agents is necessary before invasive diagnostic procedures such as lumbar puncture, arterial blood gas determination, or any endoscopy with biopsy.

Hemophilia –B Factor IX In absence of an inhibitor, each unit of FIX per kilogram of body weight infused intravenously will raise the plasma FIX level approximately 1 IU Dl. The half-life is approximately. 18–24 hr. Recombinant FIX (rFIX) :each unit of FIX per kg body weight infused will raise the FIX activity by approximately 0.8 IU dLin adults and 0.7 IU dL1 in children under15 years of age.

Prophylaxis-long acting The long-acting recombinant Fc fusion factor IX (rFIXFc), Alprolix, was approved by the FDA in March 2014 for patients with hemophilia B.

Improvement of health and quality of life of people with hemophilia Joint and muscle damage and other sequelae of bleeding. Inhibitor development. Viral infection(s) transmitted through blood Products.

obligate carrier of hemophilia B The biological daughter of a man who has hemophilia. The biological mother of more than one son with hemophilia. The biological mother of at least one son with hemophilia and has at least one other blood relative with the disorder.

Definition of response to treatment of acute Hemarthrosis Excellent :Complete pain relief within 8 hours and/or complete resolution of signs of bleeding after the initial injection and not requiring any further replacement therapy within 72 hours. Good:Significant pain relief and/or improvement in signs of bleeding within approximately 8 hours after a single injection, but requiring more than one dose of replacement therapy within 72 hours for complete resolution Moderate :Modest pain relief and/or improvement in signs of bleeding within approximately 8 hours after the initial injection and requiring more than one injection within 72 hours but without complete resolution None :None or minimal improvement, or condition worsens, within approximately 8 h after the initial injection.

Muscle hemorrhage Sites of muscle bleeding that are associated with neurovascular compromise, such as the deep flexor muscle groups of the limbs, require immediate management to prevent permanent damage and loss of function. These groups include: the iliopsoas muscle (risk of femorocutaneous,crural, and femoral nerve palsy) the superior-posterior and deep posterior compartments of the lower leg (risk of posterior tibial and deep peroneal nerve injury). the flexor group of forearm muscles (risk of Volkmann’s ischemic contracture).

Principles of care The primary aim of care is to prevent and treat bleeding with the deficient clotting factor. 2. Whenever possible, specific factor deficiency should be treated with specific factor concentrate. 3. People with hemophilia are best managed in a comprehensive care setting . 4. Acute bleeds should be treated as quickly as possible, preferably within 2 h. If in doubt, treat

Definitions of factor replacement therapy protocols Secondary prophylaxis Regular continuous treatment started after2 or more bleeds into large joints and before the onset of joint disease documented by physical examination and imaging studies. Tertiary prophylaxis Regular continuous treatment started after the onset of joint disease documented by physical examination and plain radiographs of the affected joints. Intermittent (periodic) prophylaxis: Treatment given to prevent bleeding for periods not exceeding 45 weeks in a year.

Vein Access They are the lifelines for a person with hemophilia. 23- or 25-gauge butterfly needles are recommended. Never cut down into a vein, except in an emergency. Apply pressure for 3–5 min after venipuncture. Venous access devices should be avoided whenever possible, but may be required in some children.

Severity of Hemophilia B • Mild hemophilia : bleeding typically occurs only after injury, trauma, or surgery. About 25% of the hemophilia population has mild deficiency. • Moderate hemophilia :bleeding tends to occur after minor injuries, though spontaneous bleeding episodes may occur. About 15% of the hemophilia population has moderate deficiency. • Severe hemophilia :may experience not only bleeding after injury, trauma, or surgery, but also spontaneous bleeding into joints and muscles. About 60% of the hemophilia population has severe factor deficiency.

Joint hemorrhage (Hemarthrosis) The goal of treatment of acute Hemarthrosis is to stop the bleeding as soon as possible. This should ideally occur as soon as the patient recognizes the “aura”, rather than after the onset of overt swelling and pain. Further evaluation is necessary if the patient’s symptoms continue longer than 3 days. The presence of inhibitors, septic arthritis, or fracture should be considered if symptoms and findings persist.

Hemophilia B-Signs & Symptoms The hallmark of hemophilia is hemorrhage into the joints(typically the ankles in children, and the ankles, knees, and elbows in adolescents and adults). This bleeding is painful.

Management Most bleeds will require factor replacement except for bruises and minor soft tissue injuries that do not impact on function and mobility.  Invasive procedures such as arterial puncture, lumbar puncture must only be performed after clotting factor replacement. Do not give IM injections.

Physical activity Non-contact sports such as swimming, walking, golf, badminton, archery, cycling, rowing, sailing, table tennis

• More by User

Hemophilia By: Ava Foudeh What is it?

2.02k views • 16 slides

HEMOPHILIA. John O’Sullivan 24 May 2001. Outline. Definition Epidemiology Diagnosis Factor Replacement Hemophilic Arthropathy Treatment Other Topics. Hemophilia. Disorder of hemostasis, a coagulopathy Hemophilia A - Factor VIII deficiency Hemophilia B – Factor IX deficiency

824 views • 24 slides

Hemophilia. Gabriel Vacaliuc, Ethan Kridelbaugh. Chad Kroeger:. Chad has suffered the effects of hemophilia since birth. He is one of the many hemophiliacs who have hemophilia A. Inheritance and Genes Affected:.

778 views • 11 slides

http:// www.rayur.com /hemophilia-definition-causes-symptoms-diagnosis-treatment-and-prevent.html. Hemophilia. By: Anna Exley and Jolie Hassenflow. http:// theviewspaper.net /hemophilia-the-royal-disease/. Hemophilia is….

790 views • 10 slides

Richard Paul Period 7 11/15/2011. Hemophilia. Symptoms. Hemophilia is characterized by the inability to clot. In mild cases, abnormal bleeding can occur after trauma or surgery.

458 views • 9 slides

Hemophilia. David Ziga &amp; Ryan Ehlers. What is Hemophilia?. Hemophilia is caused by an abnormal gene causing bleeding in the joints. Hemophilia slows down the blood clotting process and causes prolonged bleeding after injury . Symtoms.

969 views • 7 slides

Hemophilia. Sarah Moreno Ms.Brown Child dev. -6. Definition.

504 views • 14 slides

Definition: Hemophilia is a genetic disorder passed from one generation to the next through the X (female) chromosome. It is a disease in which the blood does not clot normally, due to abnormalities in some blood proteins that cause clotting. Hemophilia. Hemophilia A.

1.1k views • 12 slides

HEMOPHILIA. By: Jess Gardner a nd Claire Griffin. Changes in the F8 gene are responsible for hemophilia A while mutations in the F9 gene cause hemophilia B.

548 views • 18 slides

Anthony Triplin Steve Jean Jude Saint-Jean February 1, 2010 Period:3. Hemophilia . Hemophilia. Blood does not clot as quickly Most common in males Also known as Christmas disease Double vision, repeated vomiting, extreme fatigue Only males get type A and B Females get type C

678 views • 12 slides

Hemophilia. By: Katey Caven &amp; Johnny Breckinridge. Inheritance. Hemophilia is a sex-linked trait 50% chance of sending it to offspring if parents have Hemophilia It is a sex-linked trait Carried by the mother on the X chromosome DID YOU KNOW! Hemophilia is a recessive allele.

436 views • 13 slides

Hemophilia. Galila Zaher Consultant Hematologist MRCPath KAUH. Prevalence. World-wide occurs in all racial groups. Few decades ago, children with haemophilia had a significantly reduced life expectancy. Crippled with arthritis &amp;joint deformity

1.01k views • 58 slides

Hemophilia. Improving quality of life …until a cure…through L ower mortality I mproved outcomes F ewer hospitalizations E ducated independent patients. 2000, Soucie, et al Mortality in hemophilia 1998, Nuss et al, Medical care in hemophilia. www.hemoalliance.org.

587 views • 24 slides

Hemophilia. Galila Zaher Consultant Hematologist MRCPath KAUH. Prevalence. World-wide occurs in all racial groups. Few decades ago, children with hemophilia had a significantly reduced life expectancy. Crippled with arthritis &amp;joint deformity

740 views • 44 slides

Hemophilia. Gerik Moeller, Kual Jiel. Background/ History. The earliest account of the condition was recorded by Dr. John Conrad Otto, in 1803. The physician discovered that the disorder was hereditary and more evident in males than in females.

224 views • 7 slides

Hemophilia. By: Lauren Donnangelo. Symptoms. Excessive bleeding after surgery, trauma, or injury Sudden or unexplained bleeding Bruised and swollen muscles or joints Deformed joints Bloody urine or stool Severe bruising Frequent nosebleeds

367 views • 8 slides

Hemophilia B-Case Report

Hemophilia B-Case Report. Bijan Keikhaei, Ahvaz Jundishapur University of Medical Sciences. Case Presentation. A 25 years old man admitted in hospital with complaints of abdominal pain , hematemesis , and melena .

1.01k views • 35 slides

Hemophilia. Hadeeth Zaidi Period 6. What it does/Causes. The disease (only present in males) lowers the level of blood plasma clotting factors which are needed for coagulation

415 views • 10 slides

Hemophilia. from Greek haima &quot;blood&quot; + philia &quot;to love&quot;. What is It and Who Is Affected?. “Coagulopathy” A genetic bleeding disorder A protein necessary to form a clot is missing 20,000 males in the U.S. A “rare disease” if occurs in less than 200,000 individuals

311 views • 9 slides

Hemophilia. What is Hemophilia?. Prevents blood from clotting properly. Types of Hemophilia…. Mild, Moderate, or severe: - Hemophilia A - Hemophilia B - Hemophilia C. Diagnostic Tests…. Hematologists: (Usually don’t test until first abnormal bleeding episode) ‏ Family history.

1.78k views • 14 slides

Hemophilia B Pipeline Review H2 2015

Hemophilia B - Pipeline Review, H2 2015 market research report is the latest addition to RnRMarketResearch.com and its collection of Hematology therapeutics business intelligence reports aimed to help take better decisions

207 views • 6 slides